Both treatment conditions enhanced phospho-tyrosine Stat3 level in the T24 bladder cancer and the human PDX model (Fig. 6b, c), which was significantly diminished by a CD167a/DDR1 selective kinase inhibitor (DDR1-IN-1) (Fig. 6b, c). This evidence concerns the gene DDR1 and urinary bladder cancer.